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Objectives: Coronavirus disease 2019 is caused by severe acute
respiratory syndrome-coronavirus-2 infection to which there is no
community immunity. Patients admitted to ICUs have high mortality, with only supportive therapies available. Our aim was to profile
plasma inflammatory analytes to help understand the host response
to coronavirus disease 2019.
Design: Daily blood inflammation profiling with immunoassays.
Setting: Tertiary care ICU and academic laboratory.
Subjects: All patients admitted to the ICU suspected of being infected
with severe acute respiratory syndrome-coronavirus-2, using standardized hospital screening methodologies, had daily blood samples
collected until either testing was confirmed negative on ICU day 3
(coronavirus disease 2019 negative), or until ICU day 7 if the patient
was positive (coronavirus disease 2019 positive).
Interventions: None.
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Measurements and Main Results: Age- and sex-matched healthy
controls and ICU patients that were either coronavirus disease
2019 positive or coronavirus disease 2019 negative were enrolled.
Cohorts were well-balanced with the exception that coronavirus disease 2019 positive patients were more likely than coronavirus disease 2019 negative patients to suffer bilateral pneumonia. Mortality
rate for coronavirus disease 2019 positive ICU patients was 40%.
We measured 57 inflammatory analytes and then analyzed with both
conventional statistics and machine learning. Twenty inflammatory
analytes were different between coronavirus disease 2019 positive
patients and healthy controls (p < 0.01). Compared with coronavirus
disease 2019 negative patients, coronavirus disease 2019 positive
patients had 17 elevated inflammatory analytes on one or more of
their ICU days 1–3 (p < 0.01), with feature classification identifying the top six analytes between cohorts as tumor necrosis factor,
granzyme B, heat shock protein 70, interleukin-18, interferon-gammainducible protein 10, and elastase 2. While tumor necrosis factor,
granzyme B, heat shock protein 70, and interleukin-18 were elevated
for all seven ICU days, interferon-gamma-inducible protein 10 transiently elevated on ICU days 2 and 3 and elastase 2 increased over
ICU days 2–7. Inflammation profiling predicted coronavirus disease
2019 status with 98% accuracy, whereas elevated heat shock protein 70 was strongly associated with mortality.
Conclusions: While many inflammatory analytes were elevated in coronavirus disease 2019 positive ICU patients, relative to healthy controls,
the top six analytes distinguishing coronavirus disease 2019 positive
ICU patients from coronavirus disease 2019 negative ICU patients
were tumor necrosis factor, granzyme B, heat shock protein 70, interleukin-18, interferon-gamma-inducible protein 10, and elastase 2.
Key Words: coronavirus disease 2019, intensive care unit, host
response, inflammation, biomarkers

C

oronavirus disease 2019 (COVID-19) is caused by the novel
coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Confirmed cases of COVID-19 are
www.ccejournal.org
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growing rapidly with spread to 188 countries and regions (1). The
number of reported mortalities worldwide is more than 435,000
predicting a case-fatality rate of approximately 3.4% (2). Based on
data from other centers, COVID-19 often results in acute respiratory distress syndrome (ARDS) with the leading cause of death
in COVID-19 positive (+) patients being respiratory failure with
or without multiple organ dysfunction (i.e., cardiac and/or renal)
(3–6). Currently, there are no specific therapies for COVID-19,
and patients are provided only supportive care.
Recent reports and commentaries have suggested that the
severity of COVID-19 may be due to a “cytokine storm” (7), which
is the excessive or uncontrolled release of cytokines in response to
a pathologic event, such as a viral infection (8). These suggestions
are due to increased inflammatory cytokine levels, such as interleukin-6 (IL-6), as well as fever, cytopenia, and hyperferritinemia
(4, 9). Moreover, these commentaries have been accompanied by
calls for the use of broad immunosuppression with steroids, IV
immunoglobulin, and/or selective cytokine blockade as a therapeutic approach for COVID-19 (8, 10). While patient mortality
could be improved with immunosuppressive therapies, the evidence for changes in specific cytokines is incomplete, and often
observed at a single timepoint with limited comparison to control
groups (4, 9). Additionally, as described in recent commentaries
and reviews, the use of immunosuppressive therapies to treat critically ill patients, including those with ARDS, has often been challenging due to the potential to cause harm highlighting the need
for rigorous data to support any proposed trials (11, 12).
The overall aim of this study was to characterize the inflammatory profile of critically ill COVID-19 patients over the first 7 days
of ICU stay to potentially identify therapeutic targets. Our specific
objectives were 1) to determine the inflammatory analytes changing between COVID-19+ ICU patients and healthy controls; 2) to
determine the inflammatory analyte differences between COVID19+ and COVID-19 negative (−) ICU patients; and 3) to determine the changes in relevant inflammatory analytes over time in
COVID-19+ ICU patients.

METHODS
Study Participants and Clinical Data
This study was approved by the Western University, Human
Research Ethics Board. We enrolled consecutive patients who were
admitted to our level-3 academic ICU at London Health Sciences
Centre-Victoria Campus (London, Ontario) and were suspected
of having COVID-19 based on standard hospital screening procedures (13). We collected daily blood samples starting at admission
and up to 3 days in COVID-19− patients, or up to 7 days in COVID19+ patients. COVID-19 status was confirmed as part of standard
hospital testing by detection of two SARS-CoV-2 viral genes using
polymerase chain reaction (14). Patient baseline characteristics
were recorded at admission and included age, sex, comorbidities,
laboratory values, arterial partial pressure to inspired oxygen (P/F)
ratio, and chest radiograph findings. Although ICU severity of illness scores have not been validated in COVID-19+ patients, we calculated multiple organ dysfunction score (MODS) and Sequential
Organ Failure Assessment (SOFA) score for both COVID-19+
2
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and COVID-19− patient groups to enable objective comparison
of their illness severity. We also categorized both patient groups
as having confirmed or suspected sepsis diagnosis using Sepsis
3.0 criteria. Clinical interventions received during the observation
period were included and consisted of antibiotics, antiviral agents,
systemic corticosteroids, vasoactive medications, renal replacement therapy, high-flow oxygen therapy, and mechanical ventilation (invasive and noninvasive). Final participant groups were
constructed by age- and sex-matching COVID-19+ ICU patients
with COVID-19− ICU patients, as well as healthy controls that had
blood samples previously banked in the Translational Research
Centre, London, ON, Canada) (directed by Dr. D. D. Fraser;
https://translationalresearchcentre.com/) (15, 16).
Blood Draws
Standard operating procedures were used to ensure all samples
were treated rapidly and equally. Blood was obtained via indwelling
catheters daily in the morning and placed immediately on ice. Once
transferred to a negative pressure hood, blood was centrifuged and
plasma isolated, aliquoted at 250 µL and frozen at −80°C. All samples remained frozen until use and freeze/thaw cycles were avoided.
Analyte Measurements
Levels of 57 inflammatory analytes were determined using
multiplexed biomarker immunoassay kits according to manufacturers’ instructions (MilliporeSigma, 400 Summit Drive,
Burlington, MA) or enzyme-linked immunosorbent assay
(ELISA). For the former, plasma inflammatory analytes were
measured using a Bio-PlexTM 200 Suspension Array system
(Bio-Rad Laboratories, Hercules, CA), which used Luminex
xMAPTM fluorescent bead-based technology (Luminex Corp,
Austin, TX). Bioanalyte concentrations were calculated from
standard curves using five-parameter logistic regression in BioPlex Manager 6.1 software. For the latter, plasma levels of TIMP1
(R&D Systems Duo Set #DY970-05, diluted 1:100 or 1:200),
TIMP2 (R&D Systems Duo Set #DY971, diluted 1:100), and
TIMP3 (R&D Systems Duo Set #DY973, diluted 1:3 or 1:4) were
measured with ELISA.
Population Statistics
Medians (interquartile ranges [IQRs]) and frequency (%) were
used to report ICU patient baseline characteristics for continuous
and categorical variables, respectively; continuous variables were
compared using Mann-Whitney U tests (or Kruskal-Wallis tests,
as appropriate), and categorical variables were compared using
Fisher exact chi-square, with p < 0.05 considered statistically significant. Daily analyte concentrations were also reported as medians (IQRs), and comparisons between groups were examined
using Mann-Whitney U tests. Given the number of analytes analyzed and the risk of false positives, a p value of < 0.01 was used as
our standard for statistical significance. Receiver operating characteristic (ROC) curves were conducted to determine sensitivity
and specificity of all continuous variables for predicting mortality.
The area-under-the-curve (AUC) was calculated for each variable,
and the coordinates of the curves were then analyzed to identify
the cutoff values based on the highest sensitivity and specificity
2020 • Volume 2 • e0144
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for predicting mortality. All analyses were conducted using SPSS
version 26 (IBM Corp., Armonk, NY).
Machine Learning
COVID-19 analyte data were visualized with a nonlinear dimensionality reduction on the full data matrix using the t-distributed
stochastic nearest neighbor embedding (t-SNE) algorithm (17).
t-SNE assumes that the “optimal” representation of the data lies on
a manifold with complex geometry, but low dimension, embedded
in the full dimensional space of the raw data. For feature selection, we pooled analyte data across 1–3 ICU days for each of the
COVID-19+ and COVID-19− cohorts and normalized observations within analyte. A random forest classifier was trained on
the variables to predict COVID-19 status. A random forest is a
set of decision trees and, consequently, we were able to interrogate this collection of trees to identify the features that have the
highest predictive value (viz., those features that frequently appear
near the top of the decision tree). We limited the decision trees to
a maximum depth of five levels and constrained the forest to 50
trees to avoid overfitting the small dataset. We further explored
the ability to perform automated classification of COVID-19+
versus COVID-19− patients from their analyte spectra, conservatively employing only a single decision tree and limiting the maximum tree depth to three levels. We trained and tested the classifier
using a five-fold cross-validation approach.

RESULTS

We investigated 10 COVID-19+ ICU patients (median years of age
= 61.0; IQR = 54.8–67.0), 10 age- and sex-matched COVID-19−
ICU patients (median years of age = 58.0; IQR = 52.5–63.0), and 10
age- and sex-matched healthy controls (median years of age = 57.5;
IQR = 52.8–62.8; p = 0.686). Baseline demographic characteristics,
comorbidities, laboratory values, and chest radiograph findings
are reported in Table 1. COVID-19-ICU patients had significantly
higher unilateral pneumonia, whereas COVID-19+ ICU patients
were more likely to have bilateral pneumonia. Sepsis was confirmed
by infectious pathogen identification in only 20% of COVID-19ICU patients, while sepsis was suspected in the remaining 80%.
All other reported baseline measures were nonsignificant between
patients, although a mortality rate of 40% was determined for
COVID-19+ ICU patients.
We measured 57 inflammatory analytes in plasma using either
fluorescent bead-based multiplex technology or ELISA. Table 2
shows that 20 inflammatory analytes were significantly different between COVID-19+ ICU patients and healthy controls (the
remaining 37 nonsignificant analytes are shown in Supplemental
Table 1, Supplemental Digital Content 1, http://links.lww.com/
CCX/A209). All significantly different analytes were elevated
in COVID-19+ ICU patients relative to healthy controls except
MMP2 that was decreased.
COVID-19+ and COVID-19− cohorts were then plotted in
two dimensions following dimensionality reduction by stochastic neighbor embedding (Fig. 1A). The dimensionality reduction shows that the daily analyte measurements (ICU days 1–3)
between the two cohorts were distinct and easily separable. To
determine which analytes were most informative for COVID-19
Critical Care Explorations

status classification, we performed feature selection with a random forest classifier. The top six features were identified for the
binary outcome of COVID-19+ versus COVID-19− in the following order: tumor necrosis factor (TNF), granzyme B, heat shock
protein 70 (HSP70), interleukin-18 (IL-18), interferon-gammainducible protein 10 (IP-10), and elastase 2 (Fig. 1B). We then
trained and tested a simple decision-tree classifier that yielded a
classifier accuracy, or the ability of the analytes to predict COVID19 status, of 98% (p < 0.001, five-fold cross-validation).
Supplemental Table 2 (Supplemental Digital Content 2, http://
links.lww.com/CCX/A210) lists 17 inflammatory analytes that
were significantly different between COVID-19+ and COVID-19–
patients on any or all of ICU days 1–3 (the remaining 40 nonsignificant analytes for ICU days 1–3 are shown in Supplemental Table
3, Supplemental Digital Content 3, http://links.lww.com/CCX/
A211). All significant analytes were elevated in COVID-19+ ICU
patients relative to COVID-19– ICU patients. While many analytes
were significantly different between COVID-19+ and COVID19− patients over time, the top six analytes determined by feature
classification over ICU days 1–3 are listed first, and were TNF, granzyme B, HSP70, and IL-18; IP-10 and elastase 2 were also significantly different between COVID-19+ and COVID-19− patients,
but starting on ICU day 2. A time course for these six markers is
shown in Figure 2 over ICU days 1–3 for COVID-19– patients and
over ICU days 1–7 for COVID-19+ patients. The mean values for
these six analytes remained elevated in COVID-19+ patients across
all seven ICU days. The remainder of the analytes measured over
time are shown in Supplemental Figure 1 (Supplemental Digital
Content 4, http://links.lww.com/CCX/A212; legend, Supplemental
Digital Content 5, http://links.lww.com/CCX/A213), with some
analytes increasing (e.g., MMP1) and some decreasing (e.g., IFNγ
and IL-1RA) over seven ICU days.
The feature matrix for day 1 COVID-19+ ICU patients was
classified for mortality using a Random Forest classifier (1,000
trees) and three-fold cross-validation. As HSP70 was the leading
analyte associated with COVID-19+ death, a ROC curve was then
conducted to determine the sensitivity and specificity of HSP70
for predicting mortality. The AUC for HSP70 was 1.00, indicating perfect sensitivity and specificity for our 10 COVID-19+ ICU
patients. Using Youden’s Index, the HSP70 cutoff value for predicting mortality was >264,380 pg/mL. Of note, with the addition of
the 10 COVID-19− cases to the analysis, the AUC and the cutoff
for HSP70 remained the same.

DISCUSSION

In this study, we measured 57 inflammatory analytes in plasma
obtained from ICU patients, both COVID-19+ and COVID-19−,
as well as age- and sex-matched healthy controls. Given the number of analytes measured, we used two complimentary methods to
analyze the data, conventional population statistics and machine
learning. Our data indicate the presence of a unique inflammatory
profile characterized by early and sustained elevations in circulating TNF, granzyme B, HSP70, and IL-18. Circulating levels of
IP-10 increased transiently on ICU days 2–3 and elastase 2 was
consistently elevated on ICU days 2–7. Finally, the plasma levels of HSP70 in COVID-19+ ICU patients were associated with
www.ccejournal.org
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TABLE 1.

Subject Demographics and Clinical Data

Variable

COVID-19+ Patients

10

n
Age in years
Sex

61.0 (54.8, 67.0)
7 women:3 men

COVID-19– Patients

10
58.0 (52.5, 63.0)
7 women:3 men

Healthy Controls

p

10

1.000

57.5 (52.8, 62.8)

0.686

7 women:3 men

1.000

Multiple organ dysfunction score

4.0 (2.5, 7.3)

6.0 (3.8, 8.0)

0.251

Sequential Organ Failure Assessment Score

4.5 (2.8, 9.3)

7.5 (4.8, 11.0)

0.160

Comorbidities, n (%)
Hypertension

6 (60)

8 (80)

0.628

Diabetes

3 (30)

4 (40)

1.000

Chronic kidney disease

2 (20)

1 (10)

1.000

Cancer

2 (20)

1 (10)

1.000

Chronic obstructive pulmonary disease

0 (0)

1 (10)

1.000

Baseline labs
WBC

8.5 (6.3, 16.1)

15.3 (11.1, 23.0)

0.064

  Neutrophils

7.7 (5.7, 13.3)

12.2 (8.1, 15.2)

0.197

  Lymphocytes

0.7 (0.6, 1.0)

1.6 (0.5, 2.3)

0.141

Platelets

206 (109, 294)

184 (159, 245)

0.623

Hemoglobin

122 (102, 136)

130 (104, 142)

0.364

Creatinine

107 (55, 288)

80 (54, 147)

0.571

Chest radiograph findings, n (%)
Bilateral pneumonia

9 (90)

1 (10)

0.001a

Unilateral pneumonia

0 (0)

5 (50)

0.033a

Interstitial infiltrates

1 (10)

1 (10)

1.000

Normal

0 (0)

3 (30)

0.211

Pao2/Fio2 ratio

124 (69, 202)

172 (132, 304)

0.153

Sepsis diagnosis
Suspected

0 (0)

8 (80)

0.001a

Confirmed

10 (100)

2 (20)

0.001a

Antibiotics

10 (100)

10 (100)

1.000

Antivirals

3 (30)

0 (0)

0.211

Steroids

2 (20)

3 (30)

1.000

Vasoactive medications

7 (70)

6 (60)

1.000

Renal replacement therapy

2 (20)

1 (10)

1.000

High-flow nasal cannula

5 (50)

2 (20)

0.350

Noninvasive mechanical ventilation

6 (60)

8 (80)

0.628

Invasive mechanical ventilation

7 (70)

8 (80)

1.000

6 (60)

10 (100)

0.087

Interventions during study

Patient outcome, n (%)
Survived

COVID-19 = coronavirus disease 2019.
a
p < 0.05.
Continuous data are presented as medians (interquartile ranges).
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TABLE 2. Comparison of Coronavirus Disease 2019-Positive Patients on ICU Day 1 to Healthy
Age- and Sex-Matched Control Patients
Analyte

Coronavirus Disease
2019-Positive Patients
(n = 10)

Elastase 2

40.2 (19.0, 69.9)

Heat shock protein 70
IL-1RA
IL-6
IL-8
Monocyte chemoattractant protein-1
Monokine induced by gamma interferon

208135 (142253, 318061)

Healthy Controls (n = 10)

2.5 (1.7, 3.2)

p

< 0.001

26914 (24981, 30710)

< 0.001

123.84 (24.43, 1037.93)

4.30 (3.27, 4.77)

< 0.001

88.13 (39.35, 306.70)

0.70 (0.30, 1.56)

< 0.001

8.84 (5.67, 18.64)

2.04 (1.48, 2.71)

< 0.001

696.6 (439.9, 1093.2)

251.7 (209.0, 336.6)

< 0.001

1717 (1126, 2294)

< 0.001

10221 (6285, 41017)

MMP8

2165 (1379, 4173)

255 (128, 301)

< 0.001

Resistin

39.15 (30.26, 118.81)

11.88 (9.23, 14.09)

< 0.001

Tumor necrosis factor

194.4 (124.3, 251.8)

14.7 (10.3, 25.5)

< 0.001

IL-10

44.26 (17.80, 170.55)

IL-18

141.4 (84.6, 252.9)

Macrophage colony-stimulating factor

184.2 (127.6, 288.2)

Granzyme B

9.61 (5.33, 23.12)

0 (0, 4.95)

0.001

34.63 (16.16, 44.92)

0.001

21.7 (0, 38.0)

0.001

2.27 (1.65, 3.30)

0.002

188 (132, 460)

0.002

Thrombospondin-1

1294 (565, 2185)

Macrophage inflammatory protein-1β

44.78 (35.88, 58.30)

31.09 (24.13, 33.51)

71040 (58159, 88142)

MMP2

0.003

120458 (99649, 133271)

0.004

Neutrophil gelatinase-associated lipocalin

117.5 (92.7, 506.7)

74.90 (62.92, 90.64)

0.004

IL-15

21.96 (12.78, 49.86)

6.69 (4.79, 9.33)

0.005

Interferon-γ

18.15 (7.82, 144.80)

1.69 (0, 4.91)

0.006

IL = interleukin, MMP = matrix metalloproteinase.
Only statistically significant data are shown (all data are shown in Supplemental Fig. 1, Supplemental Digital Content 4, http://links.lww.com/CCX/A212; legend,
Supplemental Digital Content 5, http://links.lww.com/CCX/A213). Data are presented as median (interquartile ranges). Data represent analyte concentration in pg/mL.

Figure 1. A, Subjects plotted in two dimensions following dimensionality reduction by stochastic neighbor embedding (tSNE). Purple dots represent coronavirus
disease 2019-positive (COVID-19+) subjects, yellow dots represent COVID-19− subjects. The dimensionality reduction shows that based on daily plasma
analyte concentrations, the two cohorts are distinct and easily separable. The axes are dimension less. B, Feature classification demonstrating the top 15
inflammatory analytes that classify COVID-19 status in ICU patients’ days 1–3 with their % association. HSP = heat shock protein, IL = interleukin, IFN-γ =
interferon-gamma, IP = interferon-gamma-inducible protein, M-CSF = macrophage colony-stimulating factor, MIG = monokine induced by gamma interferon,
TNF = tumor necrosis factor.
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Figure 2. Time course for the top six inflammatory analytes between coronavirus disease 2019 (COVID-19)+ and COVID-19– ICU patients. Daily values are
represented as mean (± sem). *p < 0.01. HSP = heat shock protein, IL = interleukin, IP = interferon-gamma-inducible protein, TNF = tumor necrosis factor.

mortality. Despite the exploratory nature of our study, the data
generated suggest that these six inflammatory analytes could
be considered for further investigation as potential biomarkers
and/or therapeutic targets. While changes in some potentially
useful inflammatory analytes were not identified in our study,
larger cohorts will be necessary to elucidate their role in the host
response (i.e., IL-6 required 47 patients per cohort to reach statistical significance based on 80% power and an alpha = 0.01).
Our COVID-19+ ICU patients were similar to those reported
in earlier cohorts from China (4, 5), Seattle (3), and Italy (6) with
respect to age, comorbidities, and clinical presentation. In contrast to COVID-19− ICU patients, and in keeping with findings from the Seattle cohort, our COVID-19+ ICU patients had
a higher prevalence of bilateral pneumonia. COVID-19− ICU
6
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patients had higher illness severity scores than COVID-19+ ICU
patients, although these differences were not statistically significant due to our small sample size. Given that ventilated COVID19+ ICU patients are reported to have higher mortality (18)
than comparable ARDS cohorts (19), and that MODS and SOFA
scores have not been validated in COVID-19+ ICU patients, the
lower median MODS and SOFA scores in these patients may not
accurately represent their illness severity relative to the COVID19− ICU patients. Indeed, mortality was 40% in our COVID-19+
ICU patients, whereas all COVID-19− ICU patients survived to
discharge.
Compared with healthy controls, COVID-19+ ICU patients
exhibit clinical and laboratory evidence of systemic inflammation. Increased circulating cytokine levels (e.g., TNF, IL-6, IL-8,
2020 • Volume 2 • e0144
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and IL-10), together with lymphopenia (in CD4+ and CD8+ T
cells), characterize the purported “cytokine storm” associated with
severe COVID-19. The mediator release pattern has been compared with that seen in secondary hemophagocytic lymphohistiocytosis, a hyperinflammatory syndrome commonly triggered by
viral infections, and in a small percentage of severe sepsis patients,
characterized by a fulminant and fatal hypercytokinaemia with
multiple organ failure. However, when compared with COVID19− ICU patients, the COVID-19+ ICU patients exhibited a pattern of cytokine elevation that was unique from previous reports
in that elevations were sustained and dominated by TNF and the
serine proteases granzyme B and elastase 2. These latter findings
may be of particular clinical relevance as preclinical models suggest SARS-CoV-2 entry into cells may be blocked by protease
inhibitors (20).
In contrast to other studies of sepsis and ARDS, we found persistently elevated levels of circulating TNF in our COVID-19+
ICU patients, a potent acute master regulator of the proinflammatory response. TNF is typically upregulated quickly and early
following exposure to an invading pathogen or to tissue damage,
after which secondary mediators propagate inflammation while
circulating levels of TNF quickly normalize (21, 22). The persistently elevated levels of TNF in COVID-19+ ICU patients could
be a potential target for anti-TNF therapy with either neutralizing
antibodies or small molecule inhibitors (10).
Granzyme B is expressed specifically in the cytolytic granules
of natural killer cells and cytotoxic T lymphocytes, and functions
as a targeted cell death mediator traditionally considered to cause
apoptosis of tumor and virally infected cells (23). Extracellular soluble granzyme B levels are elevated in autoimmune diseases and
infections including the human endotoxemia model and in those
with severe sepsis (24). Furthermore, granzyme B retains much
of its proteolytic activity when exposed to plasma. Granzyme B
can degrade several extracellular membrane components and is
involved in the production, release, and/or processing of proinflammatory cytokines (25, 26). Granzyme B activates IL-18
through cleavage of pro-IL-18 (27, 28), which in turn promotes
cellular apoptosis via induction of granzyme B. Activation of
IL-18 also induces synthesis and release of the antiviral response
mediator’s interferon-gamma (IFNγ). Moreover, IL-18 is known
to increase adhesion molecule expression in endothelial cells,
both ICAM1 and VCAM1, thereby increasing microvascular leukocyte adhesion (29).
HSP70 was elevated in our COVID-19 ICU patients and associated with mortality. As a chaperone protein that is induced
in response to environmental, physical, and chemical stresses,
HSP70 is usually cytoprotective by limiting the consequences of
damage and by facilitating cellular recovery via caspase inhibition. Conversely, HSP70 can also exacerbate the stress response,
signaling tissue destruction, and aid in immunosurveillance by
transporting intracellular peptides to distant immune cells (30).
Extracellular HSP70 also promotes inflammation by activating
Toll-like receptors and promoting entry of granzyme B into the
cells initiating cellular apoptosis (23, 31). Interestingly, HSP70
is part of the receptor complex that interacts with the binding domain of the spike protein of infectious bronchitis virus, a
Critical Care Explorations

member of the family Coronaviridae, enabling viral entry into
lung and kidney cells (32).
IP-10 is an inflammatory chemokine released by monocytes
and endothelial cells, which aids recruitment of activated T cells
into sites of tissue inflammation. Either protecting or promoting
infection, the actions of IP-10 depend on host immune status and
genetic background (33). Previous studies suggest that IP-10 is
protective in coronavirus-induced severe acute respiratory syndrome (SARS) (34, 35), whereas others have shown improved
infectious disease outcomes after blocking IP-10 with neutralizing
antibodies (33).
Elastase 2 is also a serine protease that slowly increases in
COVID-19+ ICU patients over 7 ICU days. Neutrophil azurophilic granules, as well as monocytes/macrophages and mast cells,
contain elastase 2 (36). Upon degranulation, elastase 2 is either
released into circulation or mobilized to the leukocyte plasma
membranes and subsequently deposited to vascular endothelium
or subendothelial spaces (37, 38). In COVID-19+ ICU patients,
elevated elastase 2 levels may contribute to increased pulmonary
vascular permeability and injury. Elevated elastase 2 has been
demonstrated under various severe inflammatory conditions and
can contribute to the development of ARDS (39).
Our exploratory study has identified a unique pattern of
inflammation in COVID-19+ ICU patients that could be considered for further study as biomarkers and/or therapeutic targeting
(hypothesis-generating data); however, our study also has several
limitations. First, we only studied critically ill patients and we
cannot determine the inflammatory changes contributing to ICU
admissions. Second, given the limited number of patients available
for study, we used two complimentary methods to independently
analyze our data and both methods arrived at similar conclusions.
Third, our COVID-19 study population was relatively small; however, we still generated strongly significant data (e.g., true positives) and fulfilled an urgent need for exploratory data to focus
future hypothesis-driven studies on larger cohorts. Finally, we
report only mortality as a clinical outcome. Future studies with
larger sample sizes can explore whether reported changes in
inflammatory analytes correlate with additional clinical outcomes
such as functional status in survivors.
In summary, we report sustained elevations in a unique combination of inflammatory analytes in COVID-19+ ICU patients.
Our exploratory data are consistent with the slow, or absent
improvement in COVID-19+ patients despite state-of-the-art
ICU care, and could aid future hypothesis-driven research using
larger ICU cohorts.
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